Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Receivables (2019 - 2025)

C4 Therapeutics' Change in Receivables history spans 7 years, with the latest figure at -$4.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 42.8% year-over-year to -$4.1 million; the TTM value through Dec 2025 reached -$701000.0, up 91.94%, while the annual FY2025 figure was -$701000.0, 91.94% up from the prior year.
  • Change in Receivables reached -$4.1 million in Q4 2025 per CCCC's latest filing, down from $4.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $11.3 million in Q4 2023 to a low of -$12.4 million in Q2 2024.
  • Average Change in Receivables over 5 years is -$104150.0, with a median of -$142500.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: skyrocketed 75433.33% in 2023, then plummeted 2586.2% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $871000.0 in 2021, then tumbled by 101.72% to -$15000.0 in 2022, then surged by 75433.33% to $11.3 million in 2023, then tumbled by 164.06% to -$7.2 million in 2024, then soared by 42.8% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Change in Receivables are -$4.1 million (Q4 2025), $4.3 million (Q3 2025), and -$5.8 million (Q2 2025).